Forest/Cypress's milnacipran confirms fibromyalgia potential in third Phase III trial
This article was originally published in Scrip
Executive Summary
Forest Laboratoriesand Cypress Biosciences have released positive top-line Phase III data on their co-developed selective serotonin and noradrenaline (norepinephrine) reuptake inhibitor, milnacipran, for the management of fibromyalgia.